Said ZM, Subramanian VS, Vaziri ND, Said HM. Pyridoxine uptake by colonocytes: a specific and regulated carrier-mediated process. Am J Physiol Cell Physiol 294: C1192-C1197, 2008. First published March 19, 2008 doi:10.1152/ajpcell.00015.2008.-The water-soluble vitamin B 6 (pyridoxine) is important for normal cellular functions, growth, and development. The vitamin is obtained from two exogenous sources: a dietary source, which is absorbed in the small intestine, and a bacterial source, where the vitamin is synthesized in significant quantities by the normal microflora of the large intestine. Evidence exists to suggest the bioavailability of the latter source of the vitamin, but nothing is known about the mechanism involved and its regulation. In this study, we addressed these issues using young adult mouse colonic epithelial (YAMC) cells and human colonic apical membrane vesicles (AMV) as models and using [ 3 H]pyridoxine as the uptake substrate. The results showed the initial rate of [ 3 H]pyridoxine uptake by YAMC cells to be 1) energy-and temperature-(but not Na-) dependent and to occur without metabolic alteration in the transported substrate; 2) saturable as a function of concentration with an apparent Km and Vmax of 2.1 Ϯ 0.5 M and 53.4 Ϯ 4.3 pmol ⅐ mg protein Ϫ1 ⅐ 3 min Ϫ1 , respectively; 3) cis-inhibited by unlabeled pyridoxine and its structural analogs, but not by the unrelated compounds theophylline, penicillamine, and isoniazid; 4) trans-stimulated by unlabeled pyridoxine; 5) amiloride sensitive; and 6) regulated by extracellular and intracellular factors. Uptake of pyridoxine by native human colonic AMV was also found to involve a carrier-mediated process. These studies demonstrate, for the first time, the functional existence of a specific and regulatable carriermediated process for pyridoxine uptake by mammalian colonocytes. colonic transport; transport mechanism; transport regulation THE WATER-SOLUBLE VITAMIN B 6 represents a group of three related compounds (pyridoxine, pyridoxal, and pyridoxamine) and their phosphorylated forms. Of these compounds, pyridoxal 5Ј-phosphate represents the major biologically active form of vitamin B 6 , while pyridoxine is the form that is commonly used in nutritional supplements and vitamin preparations. Furthermore, both pyridoxine and pyridoxamine are converted into pyridoxal phosphate in the body. Vitamin B 6 plays an essential role as a cofactor in a variety of metabolic reactions that include amino acid (homocysteine), carbohydrate, and neurotransmitter metabolism, as well as sphingolipid biosynthesis (13). Recent studies have described a role for vitamin B 6 in the protection against reactive oxygen free radicals by showing that pyridoxine and pyridoxal are as effective antioxidants as vitamin C and vitamin E (2, 6). Deficiency of vitamin B 6 in humans, which could lead to a variety of clinical abnormalities that include neurological disorders, occurs in conditions like chronic alcoholism and diabetes, in patients with celiac and renal diseases, and following long-term use of hydrazines (e.g., isoniazid) and penicillamine (see Ref. 13 for review) . On the other hand, pyridoxine supplementation is effective in the treatment of pyridoxine-dependent seizures in neonates and infants, caused by an autosomal recessive inborn error of metabolism that is believed to be due to an abnormality in cellular pyridoxine uptake (7).
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Vitamin B 6 is synthesized by plant cells and most unicellular microorganisms, but humans and other mammals cannot synthesize the vitamin and thus must obtain it from exogenous sources via intestinal absorption. Two sources of vitamin B 6 are available to the intestine: a dietary source and a bacterial source; the latter source is in reference to the vitamin B 6 that is produced by the normal microflora of the large intestine. The mechanism of absorption of dietary vitamin B 6 in the small intestine has been studied using a variety of small intestinal preparations (8, 14, 15, 20, 23) , with recent findings showing the existence of an efficient and specific carrier-mediated mechanism (20, 23) . Nothing, however, is known about the mechanism of uptake of the bacterially produced vitamin B 6 in the large intestine, where a significant amount of the vitamin is produced and exists in the free form in the surrounding medium (i.e., rather than being trapped within the bacterial cells) (16) and thus is available for absorption. Evidence suggesting that this source of vitamin B 6 is indeed bioavailable to the host comes from studies showing that the amount of the vitamin that is excreted is significantly higher than the total amount consumed orally (11) . Our aim in the present study was to investigate the mechanism involved in vitamin B 6 (pyridoxine) uptake by mammalian colonocytes using the young adult mouse colonic epithelial (YAMC) cells and purified human colonic apical membrane vesicles (AMV) as models. The results showed, for the first time, the existence of a specific carrier-mediated mechanism for pyridoxine in mammalian colonocytes, which appears to be under extracellular and intracellular regulation.
MATERIALS AND METHODS

Materials.
The YAMC cells were provided as a gift from Dr. Robert Whitehead (Vanderbilt University Medical Center, Nashville, TN) (17, 25) . [ 3 H]pyridoxine (specific activity of 20 Ci/mmol; radiochemical purity Ͼ97%) was obtained from ARC (St. Louis, MO). Unlabeled pyridoxine and all other chemicals and reagents were purchased from commercial sources and were of analytical grade.
Cell culture and uptake assays. YAMC, conditionally immortalized murine colonic epithelial cells, were maintained at 33°C in Dulbecco's modified Eagle's medium (DMEM) without added pyridoxine (Life Technologies). Media were supplemented with 10% fetal bovine serum (FBS), glutamine (0.29 g/l), sodium bicarbonate (3.7 g/l), penicillin (100,000 U/l), and streptomycin (10 mg/l). Purified human colonic membrane vesicles were obtained from Dr. Pradeep Dudeja (University of Illinois at Chicago, Chicago, IL) and were isolated from organ donors as described by us previously (5) . [ 3 H]pyridoxine uptake in colonic membrane vesicle was measured at room temperature for 1 min by rapid filtration method (9) as previously described (5). Routine [ 3 H]pyridoxine uptake assay was performed using confluent monolayer (3-4 days after confluence) of YAMC in a 12-well plate. Protein concentrations were estimated on parallel wells using a protein assay kit (Bio-Rad). To determine the degree of pyridoxine metabolism after uptake by YAMC cells, a thin-layer chromatography (TLC) procedure employing cellulose gelprecoated plates and a solvent system of isopropanol/0.5 M acetate buffer (pH 4.5)/water (65/15/20, vol/vol/vol) was used as described previously (22, 23) .
Statistical analysis. Data of all uptake experiments are the results of at least three independent determinations and are expressed as means Ϯ SE (in pmol ⅐ mg protein
. Statistical analysis was performed using ANOVA or Students t-test, with a significant P value set at Ͻ0.05. Kinetic parameters of the saturable component of pyridoxine uptake were determined by subtracting the diffusion component [calculated from the slope of the line between uptake at high concentration (1 mM) and the point of origin] from total uptake; data were then applied to a computerized model of the Michaelis-Menten equation as described previously (26) .
RESULTS
Uptake of pyridoxine by YAMC cells: time course; effect of buffer pH, Na
ϩ , and temperature; and possible metabolism during transport. Pyridoxine uptake by YAMC cells as a function of incubation time was linear for up to 10 min of incubation (rate ϭ 170.5 fmol/mg protein and 17.9 pmol/mg protein for 15 nM and 3 M, respectively; r ϭ 0.99 for both; Fig. 1 ). A 3-min incubation time was chosen to represent the initial rate of uptake in all subsequent investigations. The effect of incubation buffer pH on pyridoxine uptake by YAMC cells was examined to determine the role of H ϩ pyridoxine uptake. Uptake of pyridoxine (15 nM) was relatively high over the pH range of 6.5 to 8.0 but decreased at lower pH (Fig. 2 ). For this reason, an incubation buffer pH of 7.4 was used in all reported studies.
The role of Na ϩ in pyridoxine uptake was investigated by determining the effect of iso-osmotic replacement of Na ϩ in the incubation buffer with K ϩ , Li ϩ , or mannitol. The results showed similar initial rate of pyridoxine (15 nM) uptake in the presence and absence of Na ϩ (850 Ϯ 40, 860 Ϯ 80, 880 Ϯ 30, and 830 Ϯ 50 fmol⅐ mg protein Ϫ1 ⅐3 min Ϫ1 in the presence of Na ϩ , K ϩ , Li ϩ , and mannitol, respectively). In a related study, we pretreated YAMC monolayer (for 30 min) with the Na ϩ , K ϩ -ATPase inhibitor ouabain (10 mM) and examined the effect of that pretreatment on pyridoxine uptake. No significant inhibition was observed in the initial rate of pyridoxine (15 nM) uptake following pretreatment with ouabain (771 Ϯ 38 and 845 Ϯ 18 fmol⅐mg protein Ϫ1 ⅐3 min Ϫ1 for control and ouabain-pretreated cells, respectively).
The effect of incubation temperature on [ 3 H]pyridoxine uptake by YAMC cells was also examined. Uptake was found to be highly temperature dependent, with a higher uptake at 37°C compared with 22°C (760 Ϯ 50 and 220 Ϯ 10 fmol⅐mg protein
, respectively). The metabolic form of the transported radioactivity taken by confluent YAMC cells following 10-min incubation with [ 3 H]pyridoxine (75 nM) was examined by means of TLC (see MATERIALS AND METHODS), with the majority (96%) of the transported substrate found to be in the form of intact pyridoxine.
Evidence for existence of a carrier-mediated process for pyridoxine uptake by colonocytes. The initial rate of pyridoxine uptake as a function of substrate concentration (0.1-10 M) was examined, with the results showing evidence for the existence of a saturable uptake process (Fig. 3) . Kinetic parameters of the saturable components were determined as described in MATERIALS AND METHODS and were found to be 2.1 Ϯ 0.5 M and 53.4 Ϯ 4.3 pmol⅐mg protein Ϫ1 ⅐3 min Ϫ1 for the apparent K m and V max , respectively. This finding suggests involvement of a carrier-mediated process for pyridoxine uptake by YAMC cells. To further confirm the existence of a carrier-mediated system for pyridoxine uptake and to develop an understanding of its specificity, we examined the effect of unlabeled pyridoxine and that of its related compounds pyridoxal, pyridoxal 5-phosphate, and pyridoxamine, as well as that of the unrelated isoniazid, penicillamine, theophylline, and homocystine (all at 50 M) on the initial rate of [ 3 H]pyridoxine (15 nM) uptake. The results showed that while unlabeled pyridoxine, pyridoxal, pyridoxal 5-phosphate, and pyridoxamine all cause significant (P Ͻ 0.01) inhibition in [
3 H]pyridoxine uptake, no such effect was seen with isoniazid, penicillamine, theophylline, and homocystine (Fig. 4) .
In another study, we investigated possible trans-stimulation in We also aimed at establishing the existence of a carriermediated process for pyridoxine uptake in native human colonocytes. To this end, we used purified native human proximal colonic AMV isolated by an established procedure from the colonic mucosa of human organ donors (5) and examined the effect of unlabeled pyridoxine (1 mM) on the initial rate of [ 3 H]pyridoxine (250 nM) uptake. Significant (P Ͻ 0.01) inhibition in [ 3 H]pyridoxine uptake by unlabeled pyridoxine was observed (Fig. 5) .
Effect of metabolic and transport inhibitors on [ 3 H]pyridoxine uptake by YAMC cells. Energy dependence of the pyridoxine uptake process by YAMC cells was examined by testing the effect of pretreating the cells with the metabolic inhibitors 2,4-dinitrophenol (DNP; 1 mM) and iodoacetate (1 mM) for 30 min on the initial rate of pyridoxine (15 nM) uptake. The results showed significant (P Ͻ 0.01 for both) inhibition in the vitamin uptake by both inhibitors (502 Ϯ 11, 230 Ϯ 20, and 237 Ϯ 35 fmol⅐mg protein Ϫ1 ⅐3 min Ϫ1 for control and in the presence of DNP and iodoacetate, respectively).
The membrane transport inhibitor amiloride has been shown to inhibit pyridoxine uptake in mammalian and other cellular systems (3, 4, (22) (23) (24) . We therefore examined its effect and that of other membrane transport inhibitors (DIDS and probenecid) on the initial rate of [ 3 H]pyridoxine (15 nM) uptake by YAMC cells. The results showed amiloride to cause a significant (P Ͻ 0.01) and concentration-dependent inhibition in pyridoxine uptake (737 Ϯ 49, 297 Ϯ 60, and 227 Ϯ 56 fmol⅐ mg protein Ϫ1 ⅐3 min Ϫ1 for control and in the presence of 0.1 and 1 mM amiloride, respectively). On the other hand, neither DIDS nor probenecid was found to affect the initial rate of pyridoxine uptake (737 Ϯ 49, 720 Ϯ 60, and 720 Ϯ 50 fmol⅐ mg protein Ϫ1 ⅐3 min Ϫ1 for control and in the presence of DIDS and probenecid, respectively).
Possible regulation of the colonic pyridoxine uptake. In these investigations, we examined whether the pyridoxine uptake process of the YAMC cells is regulated by extracellular and intracellular factors. The extracellular factor that was selected for testing was increased extracellular pyridoxine level; YAMC cells were maintained (for 48 h) in a growth medium in the absence and presence of oversupplemented level (100 M) of unlabeled pyridoxine. The results showed [ 3 H]pyridoxine (15 nM) uptake by cells maintained in the presence of high pyridoxine level to be significantly (P Ͻ 0.01) lower than that of cells maintained in its absence (310 Ϯ 30 and 930 Ϯ 50 fmol⅐mg protein Ϫ1 ⅐3 min Ϫ1 , respectively). This effect was specific for pyridoxine because uptake of the unrelated folic acid (8.6 nM; pH 5.5) was similar under the two pyridoxine-level conditions (1,840 Ϯ 30 and 1,880 Ϯ 70 fmol⅐mg protein Ϫ1 ⅐3 min Ϫ1 for cell growth in the absence and presence of pyridoxine oversupplementation, respectively). To determine the level at which this adaptive regulation in the pyridoxine uptake process is taking place, we first maintained YAMC cells (for 24 h) in pyridoxine-oversupplemented (100 M) medium, then moved them to a medium that lacks pyridoxine oversupplementation in the absence or presence of the transcription inhibitor actinomycin D (0.23 M) or the translational inhibitor cyclohexamide (40 M). Incubation was then continued for an additional 24 h, followed by examination of the initial rate of [ 3 H]pyridoxine (15 nM) uptake. As before, the uptake of cells maintained in the absence of pyridoxine oversupplementation was significantly (P Ͻ 0.01) higher than the uptake of cells maintained in the presence of pyridoxine oversupplementation. This induction in pyridoxine uptake was significantly (P Ͻ 0.01 for both) inhibited in the presence of actinomycin D and cyclohexamide in the growth medium (Fig. 6) .
Possible regulation of the pyridoxine uptake process of YAMC cells by intracellular regulatory pathways focused on testing the effect of modulators of specific protein kinasemediated pathways that include Ca Ϫ1 ⅐3 min Ϫ1 for control, following pretreatment with TFP, calmidazolium, and KN-62, respectively). On the other hand, pretreatment with modulators of the PKA-mediated pathway (cAMP and forskolin, both at 1 mM) did not affect pyridoxine uptake (540 Ϯ 30, 610 Ϯ 50, and 610 Ϯ 2 fmol⅐mg protein Ϫ1 ⅐3 min Ϫ1 for control and following pretreatment with cAMP and forskolin, respectively). Similarly, modulators of the PKC-mediated pathway (all at 1 M) failed to affect pyridoxine (15 nM) uptake (560 Ϯ 30, 520 Ϯ 30, 510 Ϯ 20, and 540 Ϯ 20 fmol⅐mg protein Ϫ1 ⅐3 min Ϫ1 for control and following pretreatment with phorbol 12-myristate 13-acetate, chelesthyrine, and staurosporine, respectively). Finally, we tested the potential role of the NOmediated pathway in the regulation of pyridoxine uptake by YAMC cell by examining the effect of pretreating (1 h) the cells with the NO pathway modulators 8-bromo cGMP and S-nitrose-N-acetylpenicillamine (SNAP) (both at 1 mM), but neither compound led to a significant effect an pyridoxine uptake (615 Ϯ 15, 780 Ϯ 30, and 705 Ϯ 60 fmol⅐mg protein Ϫ1 ⅐3 min Ϫ1 for control, 8-bromo cGMP, and SNAP, respectively).
DISCUSSION
As mentioned above, a considerable amount of free vitamin B 6 is synthesized by the normal microflora of the mammalian large intestine, and this vitamin exists in the colonic lumen and thus is available for absorption. Also, evidence exists to indicate that the large intestine is capable of absorbing this source of the vitamin, yet nothing is known about the mechanism involved in this absorption and its regulation. The aim of the present investigations was to address these issues using the cultured mouse colonic YAMC cells and native human colonic AMV as models, and pyridoxine as the substrate. The results showed pyridoxine uptake to be pH sensitive, with an increase in uptake at 6.5 and higher pH but decreased uptake at lower incubation buffer pH. This characteristic of pyridoxine uptake by colonic YAMC cells is similar to its characteristics in renal epithelial cells, where again uptake was found to be higher at neutral/alkaline pH compared with acidic incubation buffer pH (22) . Uptake of pyridoxine by YAMC cells was Na ϩ independent as iso-osmotic replacement of Na ϩ in the incubation buffer with other monovalent cations or mannitol, and pretreatment of the cells with the Na ϩ /K ϩ -ATPase inhibitor ouabain failed to affect the initial rate of the vitamin uptake. The latter finding on the lack of a role of Na ϩ in pyridoxine uptake is similar to what we have observed with a model of small intestinal epithelial cells (23) .
The initial rate of pyridoxine uptake by YAMC cells was saturable as a function of increasing the substrate concentration in the incubation medium (apparent K m ϭ 2.1 Ϯ 0.5 M), suggesting involvement of a carrier-mediated mechanism in the uptake process. This suggestion was confirmed by the finding of a significant cis-inhibition in the initial rate of [ 3 H]pyridoxine uptake by unlabeled pyridoxine and the pyridoxine-related compounds pyridoxal, pyridoxal 5-phosphate, and pyridoxine. Furthermore, the ability of unlabeled pyridoxine to trans-stimulate [ 3 H]pyridoxine efflux from preloaded YAMC cells lent further support for the involvement of a carrier-mediated mechanism. The inability of the unrelated penicillamine, theophylline, and homocystine to affect the initial rate of [ 3 H]pyridoxine uptake by YAMC cells demonstrates specificity of the colonic pyridoxine uptake process. In addition, since penicillamine, theophylline, and isoniazid are known inhibitors of the cytoplasmic pyridoxine kinase (which converts unphosphorylated forms of vitamin B 6 into phosphorylated forms) (10, 12) and since the initial rate of pyridoxine uptake occurs without metabolic alterations, it is reasonable to conclude that intracellular phosphorylation of the transported substrate is not involved in pyridoxine uptake by colonic epithelial cells under our experimental conditions. Not only colonocytes of mouse origin, but also human colonocytes appear to have a functional pyridoxine uptake mechanism. This conclusion is based on the observation of a significant inhibition in [ 3 H]pyridoxine uptake by unlabeled pyridoxine in purified native human colonic AMV isolated from the colonic mucosa of organ donors.
Previous studies have shown the pyridoxine uptake process of a number of prokaryotic and eukaryotic systems to be sensitive to the presence of amiloride (3, 4, (22) (23) (24) . Our findings in the present study show that the YAMC cells are not an exception to these findings because significant inhibition in pyridoxine uptake was observed in the presence of this diuretic agent in the incubation medium. Whether amiloride also interacts with the colonic pyridoxine uptake process in vivo is not clear and requires further investigation.
The colonic pyridoxine uptake process appears to be regulated by extracellular and intracellular factors. Extracellular pyridoxine level appears to exert a marked effect on pyridoxine uptake by YAMC cells. This conclusion is based on the observation that maintaining these cells in a growth medium in the absence of pyridoxine oversupplementation led to a significantly higher uptake in [ 3 H]pyridoxine compared with uptake by cells maintained in the presence of pyridoxine oversupplementation. Similar upregulation was seen with certain other water-soluble vitamin transport in a variety of cellular systems [i.e., folate, thiamine, biotin, and riboflavin transport (1, 18, 19, 21) ]. This increase in pyridoxine uptake in the absence of pyridoxine oversupplementation appears to be mediated via transcriptional/translational mechanism(s). The latter suggestion is based on the findings that the presence of actinomycin D (a transcription inhibitor) and cyclohexamide (a translation inhibitor) inhibited the induction in pyridoxine uptake caused by switching the maintenance condition of the cells from high to low pyridoxine levels. Further studies are required to delineate the exact molecular mechanism(s) involved in this adaptive response of the pyridoxine colonic uptake process by substrate availability. The colonic pyridoxine uptake process also appeared to be under intracellular regulation. This suggestion is based on the observations of inhibition in pyridoxine uptake by inhibitors of the intracellular Ca 2ϩ /CaM-mediated pathway. The cellular and molecular mechanisms that mediate the Ca 2ϩ /CaM-mediated regulation of pyridoxine uptake by colonic epithelial cells are not known, and further studies are required to address these issues. Other intracellular regulatory pathways, like the PKA-, PKC-, and NO-mediated pathways, however, appeared to exert no regulatory effect on pyridoxine uptake. These findings are similar to those observed for the pyridoxine uptake process in renal epithelial cells but are different from the findings seen with the enterocyte Caco-2 cells, where a PKA-but not a Ca 2ϩ /CaM-mediated pathway was found to play a role in the regulation of pyridoxine uptake (22, 23) . These findings suggest that different cells use different intracellular mechanisms to regulate pyridoxine uptake.
In summary, our results show for the first time the functional existence of a specific carrier-mediated mechanism for pyridoxine uptake by mammalian colonocytes. In addition, the results show that this uptake process is regulated by extracellular and intracellular factors.
